Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata

Back to Search
Print
Bookmark Trial

NCT02974868

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
University of Alabama at Birmingham, Dermatology at the Whitaker Clinic
Birmingham, Alabama, 35233, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Alopecia Areata
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female subjects between 18 75 years of age, inclusive, at time of informed consent.

- Must have moderate to severe alopecia areata:

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- History of human immunodeficiency virus (HIV) or positive HIV serology at screening,


- Infected with hepatitis B or hepatitis C viruses.


- Have evidence of active or latent or inadequately treated infection with Mycobacterium
tuberculosis (TB)


- Have received any of the following treatment regiments specified in the timeframes
outlined below:


Within 6 months of first dose of study drug: Any cell depleting agents Within 12 weeks of
first dose of study drug: Any studies with JAK inhibitors; Other biologics Within 8 weeks
of first dose of study drug: Participation in other studies involving investigational
drug(s) Within 6 weeks of first dose of study drug: Have been vaccinated with live or
attenuated live vaccine.


Within 4 weeks of first dose of study drug: Use of oral immune suppressants; Phototherapy
(NB UVB) or broad band phototherapy; Regular use (more than 2 visits per week) of a tanning
booth/parlor.


Within 2 week of first dose of study drug: Topical treatments that could affect AA; Herbal
medications with unknown properties or known beneficial effects for AA.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Alopecia AreataLong-Term PF-06651600 for the Treatment of Alopecia Areata
NCT04006457
  1. New Haven, Connecticut
  2. New Haven, Connecticut
  3. Meridian, Idaho
  4. Caba,
  5. Carlton, Victoria
  6. Bogota D.C.,
  7. Veracruz,
  8. Veracruz,
  9. Moscow,
  10. Saint Petersburg,
  11. Saint Petersburg,
  12. Taipei,
  13. Birmingham, Alabama
  14. Irvine, California
  15. Murrieta, California
  16. San Francisco, California
  17. San Francisco, California
  18. Santa Ana, California
  19. Santa Monica, California
  20. Washington, District of Columbia
  21. Washington, District of Columbia
  22. Washington, District of Columbia
  23. Washington, District of Columbia
  24. Washington, District of Columbia
  25. Boynton Beach, Florida
  26. Orange Park, Florida
  27. Tampa, Florida
  28. Oakbrook Terrace, Illinois
  29. Skokie, Illinois
  30. Springfield, Illinois
  31. Indianapolis, Indiana
  32. Chevy Chase, Maryland
  33. Boston, Massachusetts
  34. Minneapolis, Minnesota
  35. Minneapolis, Minnesota
  36. Omaha, Nebraska
  37. Verona, New Jersey
  38. New York, New York
  39. New York, New York
  40. New York, New York
  41. New York, New York
  42. Chapel Hill, North Carolina
  43. Chapel Hill, North Carolina
  44. Chapel Hill, North Carolina
  45. Tulsa, Oklahoma
  46. Vienna, Virginia
  47. Caba,
  48. Kogarah, New South Wales
  49. Kogarah, New South Wales
  50. Benowa, Queensland
  51. Woolloongabba, Queensland
  52. East Melbourne, Victoria
  53. Parkville, Victoria
  54. Parkville, Victoria
  55. Winnipeg, Manitoba
  56. London, Ontario
  57. Markham, Ontario
  58. Oakville, Ontario
  59. Peterborough, Ontario
  60. Richmond Hill, Ontario
  61. Sudbury, Ontario
  62. Sudbury, Ontario
  63. Toronto, Ontario
  64. Montreal, Quebec
  65. Quebec,
  66. Nagoya, Aichi
  67. Sendai, Miyagi
  68. Osaka-City, Osaka
  69. Hamamatsu, Shizuoka
  70. Koto-ku, Tokyo
  71. Mitaka-shi, Tokyo
  72. Busan,
  73. Seoul,
  74. Seoul,
  75. Chelyabinsk,
  76. Kirov,
  77. Moscow,
  78. Rostov-on-Don,
  79. Saint Petersburg,,
  80. Yaroslavl,
  81. Taichung, R.o.c.
  82. Kaohsiung City,
  83. Kaohsiung,
  84. New Taipei City,
  85. Taichung,
  86. Taoyuan City,
ALL GENDERS
12 Years+
years
MULTIPLE SITES
Alopecia AreataPF-06651600 for the Treatment of Alopecia Areata
NCT03732807
  1. Chevy Chase, Maryland
  2. Parkville, Victoria
  3. Birmingham, Alabama
  4. Irvine, California
  5. Murrieta, California
  6. San Francisco, California
  7. San Francisco, California
  8. Santa Ana, California
  9. Santa Monica, California
  10. Aurora, Colorado
  11. New Haven, Connecticut
  12. New Haven, Connecticut
  13. New Haven, Connecticut
  14. New Haven, Connecticut
  15. New Haven, Connecticut
  16. Washington, District of Columbia
  17. Washington, District of Columbia
  18. Washington, District of Columbia
  19. Boynton Beach, Florida
  20. Orange Park, Florida
  21. Tampa, Florida
  22. Meridian, Idaho
  23. Chicago, Illinois
  24. Chicago, Illinois
  25. Chicago, Illinois
  26. Chicago, Illinois
  27. Skokie, Illinois
  28. Springfield, Illinois
  29. Indianapolis, Indiana
  30. Iowa City, Iowa
  31. Iowa City, Iowa
  32. Boston, Massachusetts
  33. Minneapolis, Minnesota
  34. Minneapolis, Minnesota
  35. Omaha, Nebraska
  36. Verona, New Jersey
  37. New York, New York
  38. New York, New York
  39. New York, New York
  40. New York, New York
  41. Chapel Hill, North Carolina
  42. Chapel Hill, North Carolina
  43. Chapel Hill, North Carolina
  44. Cleveland, Ohio
  45. Tulsa, Oklahoma
  46. Houston, Texas
  47. Caba,
  48. Caba,
  49. Kogarah, New South Wales
  50. Kogarah, New South Wales
  51. Benowa, Queensland
  52. Woolloongabba, Queensland
  53. Carlton, Victoria
  54. East Melbourne, Victoria
  55. Parkville, Victoria
  56. Winnipeg, Manitoba
  57. Halifax, Nova Scotia
  58. London, Ontario
  59. Markham, Ontario
  60. Oakville, Ontario
  61. Peterborough, Ontario
  62. Richmond Hill, Ontario
  63. Sudbury, Ontario
  64. Sudbury, Ontario
  65. Toronto, Ontario
  66. Montreal, Quebec
  67. Quebec,
  68. Santiago, LAS Condes
  69. Santiago, Recoleta
  70. Santiago, Region Metropolitana
  71. Vina del Mar, Valparaiso
  72. Beijing, Beijing
  73. Beijing, Beijing
  74. Beijing, Beijing
  75. Guangzhou, Guangdong
  76. Shenzhen, Guangdong
  77. Wuhan, Hubei
  78. Nanjing, Jiangsu
  79. Shanghai, Shanghai
  80. Hangzhou, Zhejiang
  81. Hangzhou, Zhejiang
  82. Shanghai,
  83. Medellin, Antioquia
  84. Medellin, Antioquia
  85. Bogota, D.c.
  86. Brno,
  87. Brno,
  88. Nachod,
  89. Náchod,
  90. Olomouc,
  91. Praha 10,
  92. Praha 1,
  93. Praha 8 - Liben,
  94. Praha 8- Liben,
  95. Praha2,
  96. Bad Bentheim,
  97. Berlin,
  98. Erlangen,
  99. Frankfurt am Main,
  100. Luebeck,
  101. Luebeck,
  102. Muenster,
  103. Budapest,
  104. Debrecen,
  105. Gyongyos,
  106. Szeged,
  107. Nagoya, Aichi
  108. Sendai, Miyagi
  109. Hamamatsu, Shizuoka
  110. Koto-ku, Tokyo
  111. Shinjuku-ku, Tokyo
  112. Osaka,
  113. Busan,
  114. Seoul,
  115. Seoul,
  116. Veracruz,
  117. Krakow,
  118. Lodz,
  119. Szczecin,
  120. Warszawa,
  121. Warszawa,
  122. Wroclaw,
  123. Chelyabinsk,
  124. Kirov,
  125. Moscow,
  126. Moscow,
  127. Rostov-on-Don,
  128. Saint Petersburg,,
  129. Saint Petersburg,
  130. Saint Petersburg,
  131. Yaroslavl,
  132. Badalona, Barcelona
  133. Barcelona,
  134. Barcelona,
  135. Barcelona,
  136. Córdoba,
  137. Madrid,
  138. Madrid,
  139. Valencia,
  140. Kaohsiung City,
  141. Kaohsiung,
  142. New Taipei City,
  143. New Taipei City,
  144. Taichung,
  145. Taichung,
  146. Taipei,
  147. Taoyuan City,
  148. Taoyuan City,
  149. Brighton, EAST Sussex
  150. Southampton, Hampshire
  151. Brighton,
  152. Dundee,
  153. Glasgow,
  154. Glasgow,
  155. Hampshire,
  156. London,
  157. London,
ALL GENDERS
12 Years+
years
MULTIPLE SITES
Alopecia AreataStudy To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
NCT02974868
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Santa Ana, California
  4. Santa Monica, California
  5. Santa Monica, California
  6. Santa Monica, California
  7. Aurora, Colorado
  8. Aurora, Colorado
  9. Aurora, Colorado
  10. New Haven, Connecticut
  11. New Haven, Connecticut
  12. New Haven, Connecticut
  13. New Haven, Connecticut
  14. New Haven, Connecticut
  15. Orange Park, Florida
  16. Orange Park, Florida
  17. Tampa, Florida
  18. Tampa, Florida
  19. Tampa, Florida
  20. Tampa, Florida
  21. Newnan, Georgia
  22. Skokie, Illinois
  23. Indianapolis, Indiana
  24. Indianapolis, Indiana
  25. Boston, Massachusetts
  26. Boston, Massachusetts
  27. New York, New York
  28. New York, New York
  29. New York, New York
  30. New York, New York
  31. Rochester, New York
  32. Rochester, New York
  33. Rochester, New York
  34. Rochester, New York
  35. Tulsa, Oklahoma
  36. Rapid City, South Dakota
  37. Murray, Utah
  38. Salt Lake City, Utah
  39. Norfolk, Virginia
  40. Hurstville, New South Wales
  41. Kogarah, New South Wales
  42. Kogarah, New South Wales
  43. Kogarah, New South Wales
  44. Benowa, Queensland
  45. Woolloongabba, Queensland
  46. Carlton, Victoria
  47. East Melbourne, Victoria
  48. Richmond, Victoria
  49. Richmond, Victoria
  50. Winnipeg, Manitoba
  51. Markham, Ontario
  52. Oakville, Ontario
  53. Peterborough, Ontario
  54. Richmond Hill, Ontario
  55. Richmond Hill, Ontario
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
Official Title  ICMJE A PHASE 2A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 AND PF-06700841 IN SUBJECTS WITH MODERATE TO SEVERE ALOPECIA AREATA WITH A SINGLE-BLIND EXTENSION PERIOD AND A CROSS-OVER OPEN LABEL EXTENSION PERIOD
Brief Summary This is a Phase 2a, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 113 weeks. This includes an up to 5 weeks Screening Period, a 24 week Treatment Period, a 4 week Drug Holiday (#1), an up to 12 month Single Blind (investigator open, sponsor open and subject blind) Extension Period, a 4 week drug holiday (#2), a 6 month Cross Over Open Label Extension Period and a 4 week Follow up Period.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model Description:
The first 24 weeks are parallel. The single-blind extension period will have a segment for non-responder and a withdrawal/retreatment segment for responder. The cross-over extension period is parallel for non-responders.
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Alopecia Areata
Intervention  ICMJE
  • Drug: PF-06651600
    200 mg QD during induction and 50 mg QD during Maintenance
  • Drug: PF-06700841
    60 mg QD during induction and 30 mg QD during maintenance
  • Drug: Placebo
    Placebo
Study Arms  ICMJE
  • Experimental: Cohort 1
    PF-06651600
    Intervention: Drug: PF-06651600
  • Experimental: Cohort 2
    PF-06700841
    Intervention: Drug: PF-06700841
  • Placebo Comparator: Cohort placebo
    placebo
    Intervention: Drug: Placebo
Publications * Fensome A, Ambler CM, Arnold E, Banker ME, Brown MF, Chrencik J, Clark JD, Dowty ME, Efremov IV, Flick A, Gerstenberger BS, Gopalsamy A, Hayward MM, Hegen M, Hollingshead BD, Jussif J, Knafels JD, Limburg DC, Lin D, Lin TH, Pierce BS, Saiah E, Sharma R, Symanowicz PT, Telliez JB, Trujillo JI, Vajdos FF, Vincent F, Wan ZK, Xing L, Yang X, Yang X, Zhang L. Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). J Med Chem. 2018 Oct 11;61(19):8597-8612. doi: 10.1021/acs.jmedchem.8b00917. Epub 2018 Aug 16.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 23, 2018)		142
Original Estimated Enrollment  ICMJE
 (submitted: November 23, 2016)		132
Actual Study Completion Date  ICMJE May 15, 2019
Actual Primary Completion Date May 15, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female subjects between 18 75 years of age, inclusive, at time of informed consent.
  • Must have moderate to severe alopecia areata:

Exclusion Criteria:

  • History of human immunodeficiency virus (HIV) or positive HIV serology at screening,
  • Infected with hepatitis B or hepatitis C viruses.
  • Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)
  • Have received any of the following treatment regiments specified in the timeframes outlined below:

Within 6 months of first dose of study drug: Any cell depleting agents Within 12 weeks of first dose of study drug: Any studies with JAK inhibitors; Other biologics Within 8 weeks of first dose of study drug: Participation in other studies involving investigational drug(s) Within 6 weeks of first dose of study drug: Have been vaccinated with live or attenuated live vaccine.

Within 4 weeks of first dose of study drug: Use of oral immune suppressants; Phototherapy (NB UVB) or broad band phototherapy; Regular use (more than 2 visits per week) of a tanning booth/parlor.

Within 2 week of first dose of study drug: Topical treatments that could affect AA; Herbal medications with unknown properties or known beneficial effects for AA.

Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Canada,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02974868
Other Study ID Numbers  ICMJE B7931005
2016-004048-13 ( EudraCT Number )
ALLEGRO ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date May 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP